Fig 2: Expression of HLA-DQA2, HOXA3, SAA2, CD86, and CD8 in IDH1mt-glioma tissues. IDH1mt-glioma tissues were divided into long- and short-term survival groups according to the patient’s number of days of survival with the cut-off as 15 months. (A) The IHC score of HLA-DQA2, HOXA3, and SAA2 in IDH1mt-glioma tissues in long- and short-term groups. (B) Representative figures of expression of HLA-DQA2, HOXA3, and SAA2 in long- and short-term group IDH1mt-glioma tissues. (C) Expression of CD86 and CD8 in long- and short-term group IDH1mt-glioma tissues. (D–F) The diagnostic value of HLA-DQA2, HOXA3, and SAA2 for distinguishing long- and short-term survival of IDH1mt-glioma patients. **P < 0.01.